RK

Ravi Kant Gupta

Active Director Director DIN 00840445
DIN 00840445 First appointment Apr 1995 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 1995
Shareholding value •••• Premium profile

About Ravi Kant Gupta

Data last updated:

Ravi Kant Gupta is a Director at Booty Pharma Private Limited (since 1995). The company operates in Pharma. Booty Pharma Private Limited reported revenue of ₹1.87 Cr (FY 2024).

DIN 00840445
Primary Designation Director
Industry Pharma
First Appointment 10 Apr 1995
Oldest Company Age 31 yrs
Largest company Booty Pharma Private Limited · ₹1.87 Cr (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Booty Pharma Private Limited U24231UP1995PTC017861
Director10 Apr 19951995₹1.87 Cr (FY 2024)Active

Board colleagues of Ravi Kant Gupta

Directorship timeline

Open interactive timeline →
Booty Pharma Private Limited
Premium access

Shareholding and investment profile for Ravi Kant Gupta

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ravi Kant Gupta

Ravi Kant Gupta currently holds 1 directorship: Booty Pharma Private Limited (Director, since 10 Apr 1995, revenue ₹1.87 Cr (FY 2024)).

Ravi Kant Gupta was first appointed on 10 Apr 1995 as Director at Booty Pharma Private Limited.

The current boards of Ravi Kant Gupta's companies include Meera Gupta (Booty Pharma Private Limited), Reeshabh Gupta (Booty Pharma Private Limited), Shubham Gupta (Booty Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available